Compare AYTU & FCUV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AYTU | FCUV |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | 83 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.4M | 25.3M |
| IPO Year | N/A | N/A |
| Metric | AYTU | FCUV |
|---|---|---|
| Price | $2.33 | $3.75 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $9.33 | N/A |
| AVG Volume (30 Days) | ★ 52.7K | 20.3K |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $63,696,000.00 | $387,457.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $47.30 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.95 | $1.80 |
| 52 Week High | $2.82 | $10.90 |
| Indicator | AYTU | FCUV |
|---|---|---|
| Relative Strength Index (RSI) | 60.88 | 50.13 |
| Support Level | $2.05 | $3.30 |
| Resistance Level | $2.39 | $3.96 |
| Average True Range (ATR) | 0.10 | 0.28 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 78.57 | 49.52 |
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
Focus Universal Inc offers smart devices, IoT products, and patented products and technologies for 5G telecommunications and network security. It is focused on commercializing its universal smart technology and financial reporting software. Its product line includes various digital, analog, and quantum light meters and filtration products, the Ubiquitor universal smart device, SEC Financial Reporting Software, and other smart devices and sensors. The company's reportable segments are Corporate and IoT, which derives maximum revenue, and Perfecular and Lusher. The Corporate and IoT segment includes its LED and IoT installation and management business (under Smart AVX), specializing in LED and display systems, home theaters, lighting control, automation, and integration.